Latuda nearly doubles investment in professional health journal advertising year-over-year
Among the top 20 drugs advertising in professional health journals from the beginning of 2013 until the end of August, there have been several large increases in dollars spent when compared to the same time period of 2012.
Print Ad Drug Products with Large Increases (Dollars): Jan. – August 2013
- Xarelto - $11 MM (+32%)
- Zytiga – $3 MM (+19%)
- Brilinta Ticagrelor Tablets - $3 MM (+38%)
- Latuda – $3 MM (+92%)
- Humira - $3 MM (+32%)
Latuda is an antipsychotic medication used to treat schizophrenia in adults. Humira treats symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and other conditions.
Note that this does not include products that have launched since August 2012.
The percentage changes compare January – August 2013 to that same time period in 2012. For more information on these ad insights or other data, let one of us know.
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.